@article{oai:showa.repo.nii.ac.jp:00000476,
 author = {MANABE, Ryo and ANDO, Koichi and KUSUMOTO, Sojiro and TANAKA, Akihiko and YAMAOKA, Toshimitsu and OHMORI, Tohru and OHNISHI, Tsukasa and SAGARA, Hironori},
 issue = {2},
 journal = {The Showa University journal of medical sciences},
 month = {2018-06, 2019-07-26},
 note = {The safety and efficacy profiles of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase （ALK）-positive advanced non-small cell lung cancer still remains to be elucidated. We compared the overall efficacies of alectinib and crizotinib for previously untreated ALK-positive advanced non-small cell lung cancer through a meta-analysis of randomized controlled trials. The primary outcome was progression-free survival （PFS）. Pooled estimates were calculated as hazard ratios with 95％ confidence intervals. Two studies on alectinib met the inclusion criteria for this meta-analysis. The hazard ratio （95％ confidence interval） of alectinib for PFS, relative to crizotinib, was 0.41 （0.28-0.60）, demonstrating a superior overall efficacy of alectinib over crizotinib, in terms of PFS.},
 pages = {309--315},
 title = {Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis},
 volume = {30},
 year = {}
}